Lixisenatid (trade name Lyxumia in the European Union and Adlyxin in the U.S. and manufactured by Sanofi) is a once-daily injectable GLP-1 receptor agonist for the treatment of type 2 diabetes.
Lixisenatid (Lyxumia, Adlyxin, ZP10A-peptid, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptoragonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes.In the European Union, its use is limited to complementing insulin therapy.As of 2017 it is unclear if they affect a person's risk of death.
It is provided in an autoinjector containing fourteen doses and is injected subcutaneously.
Lixisenatide should not be used for people who have problems with stomach emptying.Lixisenatide delays emptying of the stomach, which may change how quickly other drugs that are taken by mouth take effect.
